item 2 .
properties .
we conduct our primary operations at the owned and leased facilities described below .
location operations conducted approximate square feet expiration new haven , connecticut corporate headquarters and executive , sales , research and development offices 514000 .

location
operations conducted
approximatesquare feet
leaseexpirationdates
new haven connecticut
corporate headquarters and executive sales research and development offices
514000
2030
dublin ireland
global supply chain distribution and administration offices
215000
owned
lexington massachusetts
research and development offices
81000
2019
bogart georgia
commercial research and development manufacturing
70000
2024
smithfield rhode island
commercial research and development manufacturing
67000
owned
zurich switzerland
regional executive and sales offices
69000
2025

we believe that our administrative office space is adequate to meet our needs for the foreseeable future .
we also believe that our research and development facilities and our manufacturing facility , together with third party manufacturing facilities , will be adequate for our on-going activities .
in addition to the locations above , we also lease space in other u.s .
locations and in foreign countries to support our operations as a global organization .
as of december 31 , 2015 , we also leased approximately 254000 square feet in cheshire , connecticut , which was the previous location of our corporate headquarters and executive , sales , research and development offices .
in december 2015 , we entered into an early termination of this lease and will occupy this space through may 2016 .
in april 2014 , we purchased a fill/finish facility in athlone , ireland .
following refurbishment of the facility , and after successful completion of the appropriate validation processes and regulatory approvals , the facility will become our first company-owned fill/finish and packaging facility for our commercial and clinical products .
in may 2015 , we announced plans to construct a new biologics manufacturing facility on our existing property in dublin ireland , which is expected to be completed by 2020 .
item 3 .
legal proceedings .
in may 2015 , we received a subpoena in connection with an investigation by the enforcement division of the sec requesting information related to our grant-making activities and compliance with the fcpa in various countries .
the sec also seeks information related to alexion 2019s recalls of specific lots of soliris and related securities disclosures .
in addition , in october 2015 , alexion received a request from the doj for the voluntary production of documents and other information pertaining to alexion's compliance with the fcpa .
alexion is cooperating with these investigations .
at this time , alexion is unable to predict the duration , scope or outcome of these investigations .
given the ongoing nature of these investigations , management does not currently believe a loss related to these matters is probable or that the potential magnitude of such loss or range of loss , if any , can be reasonably estimated .
item 4 .
mine safety disclosures .
not applicable. .

Question: how many square feet are leased by alexion pharmaceuticals , inc?
Answer: 734000